Clinical Trial

Evaluation Viral RNA and Virus Infectivity in Exhaled Air Before and After Use of One Dose With ColdZyme Mouth Spray

Recruiting
View on ClinicalTrials.gov →
Summary
Many respiratory diseases spread through aerosols. ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The objective of this study is assessing if ColdZyme could also contribute to decreased airborne transmission by decreasing the amount of (infectious) virus that is exhaled by an infected subject.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-19.
Status change: Not Yet Recruiting → Recruiting 2026-03-31
Trial Details
NCT Number NCT07041671
Lead Sponsor Lund University
Collaborators: Enzymatica AB
Conditions URTI - Viral Upper Respiratory Tract Infection
Enrollment 200 participants
Start Date 2025-06-30
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06